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ABSTRACT 
Background. The aim of this study was to report the course and outcome of SARS-CoV-2 infection in multiple sclerosis (MS) 
patients treated with disease-modifying therapies (DMTs) in Poland.
A major concern for neurologists worldwide is the course and outcome of SARS-CoV-2 infection in patients with MS treated 
with different DMTs. Although initial studies do not suggest an unfavourable course of infection in this group of patients, the 
data is limited.
Materials and methods. This study included 396 MS patients treated with DMTs and confirmed SARS-CoV-2 infection from 
28 Polish MS centres. Information concerning patient demographics, comorbidities, clinical course of MS, current DMT use, as 
well as symptoms of SARS-CoV-2 infection, need for pharmacotherapy, oxygen therapy, and/or hospitalisation, and short-term 
outcomes was collected up to 30 January 2021. Additional data about COVID-19 cases in the general population in Poland was 
obtained from official reports of the Polish Ministry of Health.
Results. There were 114 males (28.8%) and 282 females (71.2%). The median age was 39 years (IQR 13). The great majority of 
patients with MS exhibited relapsing-remitting course (372 patients; 93.9%). The median EDSS was 2 (SD 1.38), and the mean 
disease duration was 8.95 (IQR 8) years. Most of the MS patients were treated with dimethyl fumarate (164; 41.41%). Other DMTs 
were less frequently used: interferon beta (82; 20.70%), glatiramer acetate (42; 10.60%), natalizumab (35;8.84%), teriflunomide 
(25; 6.31%), ocrelizumab (20; 5.05%), fingolimod (16; 4.04), cladribine (5; 1.26%), mitoxantrone (3; 0.76%), ozanimod (3; 0.76%), 
and alemtuzumab (1; 0.25%). The overall hospitalisation rate due to COVID-19 in the cohort was 6.81% (27 patients). Only 
one patient (0.3%) died due to SARS-CoV-2 infection, and three (0.76%) patients were treated with mechanical ventilation; 
106 (26.8%) patients had at least one comorbid condition. There were no significant differences in the severity of SARS-CoV-2 
infection regarding patient age, duration of the disease, degree of disability (EDSS), lymphocyte count, or type of DMT used. 
Conclusions and clinical implications. Most MS patients included in this study had a favourable course of SARS-CoV-2 infec-
tion. The hospitalisation rate and the mortality rate were not higher in the MS cohort compared to the general Polish population. 
Continued multicentre data collection is needed to increase the understanding of SARS-CoV-2 infection impact on the course 
of MS in patients treated with DMTs. 
Key words: multiple sclerosis, COVID-19, SARS-CoV-2, disease-modifying therapies
(Neurol Neurochir Pol 2021; 55 (2): 212–222)
Introduction
Severe acute respiratory syndrome coronavirus-2 (SARS-
-CoV-2) is an enveloped, single-stranded, RNA virus, and 
a member of the family Coronaviridae. It was isolated for the 
first time on 7 January 2020 in China. Since the first unex-
plained pneumonia cases reported from Wuhan, China in early 
December 2019, the global spread of the novel coronavirus 
had resulted in over 100,000,000 confirmed cases and over 
2,000,000 deaths by the end of January 2021 [1, 2]. The World 
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Health Organisation (WHO) declared a pandemic in March 
2020. The current coronavirus outbreak led to a much larger 
global threat compared to previous outbreaks caused by severe 
acute respiratory syndrome (SARS-CoV) in late 2002 or the 
Middle East respiratory syndrome (MERS-CoV) in 2012 [3].
The majority of SARS-CoV-2 infections are asymptomat-
ic. The most common clinical presentation in symptomatic 
individuals is pneumonia, now termed Coronavirus Disease 
2019 (COVID-19). However, the clinical spectrum of SARS-
-CoV-2 infection is broad, and is a particular threat to those 
over 60 years of age and those with comorbidities [4]. The 
virus primarily targets the respiratory tract; however, there 
is clinical evidence of neuro-invasive properties. According 
to scientific reports published so far, 18–80% of patients can 
develop neurological symptoms such as headache, olfactory 
and gustatory dysfunctions, encephalopathy, encephalitis 
and cerebrovascular pathologies, acute myelitis, and Guil-
lain-Barré syndrome [5, 6]. The exact mechanism by which 
SARS-CoV-2 infects the central nervous system (CNS) is still 
under investigation. The entrance points to the CNS for SARS-
-CoV-2 include retrograde transfer from the olfactory nerve, 
increased permeability of the blood-brain barrier during 
the viremia phase, and a synapse-connected route from the 
peripheral nerve terminal [7].
Neurologists are interested in understanding whether 
patients with multiple sclerosis (MS) undergoing disease-mod-
ifying therapies (DMTs) are more susceptible to developing 
COVID-19 or worse clinical outcomes. The initial studies do 
not suggest an unfavourable course of the infection due to the 
use of most DMTs, although the data is limited [8–10]. Some 
immunosuppressive therapies may even play a protective 
role because overactive immune response can lead to clinical 
deterioration during the course of COVID-19 [11].
To better understand the impact of SARS-CoV-2 infection 
on the MS population, we collected data from 28 Polish MS 
centres. The aim of our study was to report symptoms, the 
course and short-term outcomes of SARS-CoV-2 infection 
in MS patients treated with different DMTs. 
Materials and methods 
Participants were recruited from 28 MS centres from across 
the country (Fig. 1). The Multiple Sclerosis and Neuroimmu-
nology Section of the Polish Neurological Society published 
an announcement about the study at www.ptneuro.pl and 
every MS centre in Poland was invited to participate. The 
data was obtained by neurologists using a pre-prepared ques-
tionnaire (the same for all MS centres). We included patients 
with a confirmed diagnosis of MS according to the 2010 and 
2017 McDonald criteria who were being treated with DMTs. 
[12, 13]. Only patients with confirmed SARS-CoV-2 infection 
were included in the study. The infection was detected by pos-
itive polymerase chain reaction (Seegene Allplex 2019 nCoV 
assay, PCR, SARS-CoV-2 Real Time PCR LAB-KIT™ by BIO-
MAXIMA S.A., GeneProof SARS-CoV-2 PCR Kit), positive 
antigen test against SARS-CoV-2 (Panbio™ COVID-19 Ag 
Rapid Test, Abbott), or the presence of antibodies against 
SARS-CoV-2 (EUROIMMUN Anty-SARS-CoV-2 ELISA 
IgA, IgG). Disability was assessed by the Expanded Disability 
Status Scale (EDSS) [14]. We collected patient demographics, 
Polish MS centres included in the study (divided by individual voivodships)
MS patients included in the study 
82 
0
Figure 1. Locations of MS centres participating in study
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Table 1. Demographics and clinical characteristics of MS cohort
Demographics No. (%) Range Mean MEDIAN IQR SD
Number of patients 396 100















EDSS 0–6.5 2.37 2 2.5 1.38
Disease duration (years) 0–33 8.95 8 8 5.91



































MS — multiple sclerosis; SD — standard deviation; RRMS — relapsing remitting multiple sclerosis; PPMS — primary progressive multiple sclerosis; SPMS — secondary progressive multiple sclerosis; EDSS — 
Expanded Disability Status Scale; DMTs — disease-modifying therapies
current DMT use, and information about the course of SARS-
-CoV-2 infection (symptoms, need for hospitalisation, oxygen 
therapy, pharmacotherapy and short-term outcome). Data 
was collected up to 30 January 2021. Additional data about 
COVID-19 cases in the general Polish population was obtained 
from official reports of the Polish Ministry of Health [15].
Demographics, MS duration, level of disability, DMT use, 
method of SARS-CoV-2 infection confirmation, symptoms, 
number of hospitalisations, treatment during SARS-CoV-2 in-
fection, and key comorbidities were reported with descriptive 
statistics, using range, mean and standard deviation or median 
and interquartile range depending on the data type. For be-
tween-group comparisons, a parametric two-sided t-test, Fish-
er’s exact p-test, and a nonparametric Mann-Whitney test were 
used. We compared age, duration of the disease, EDSS, DMT 
use, and the presence of comorbid diseases between patients 
who required oxygen therapy/hospitalisation and the rest of 
the cohort. Multivariate analysis and univariate analysis were 
used to evaluate the odds ratio for hospitalisation according 
to treatment with different DMTs. All calculations were per-
formed with STATA 15 software (StataCorp 2017) [16].
The study was approved (approval No. 6/2021) by the Bio-
ethics Committee at Collegium Medicum, Jan Kochanowski 
University in Kielce, Poland.
Results
The study finally included information about 396 MS pa-
tients with confirmed SARS-CoV-2 infection and treated with 
different DMTs. Demographics and clinical characteristics of 
the study group are set out in Table 1. 
There were 106 (26.8%) patients with at least one comorbid 
condition: 10 had two, and two subjects had three comorbid 
diseases. The most common comorbidities were: hypertension 
(44 patients; 11.1% of the cohort), diabetes in 12 (3%) patients, 
coronary artery disease in six (1.5%), asthma in nine (2.3%), 
and chronic liver disease in four (1%); 55 (13.9%) patients 
had one other comorbidity (chronic obstructive pulmonary 
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Table 2. Number of SARS-CoV-2 infection diagnoses confirmed by different diagnostic tests
No. of patients Percentage of cohort
Positive PCR 333 84
Positive antigen test confirmed by PCR 23 5.8
Positive PCR/antigen test and presence of antibodies against SARS-CoV-2 20 5
Positive antigen test against SARS-CoV-2 39 9.9









MS vs. general Polish population — hospitalisations due to COVID-19
Covfirmed COVID-19 cases in general population in Poland (left axis) 













































Figure 2. Confirmed cases of COVID-19: MS vs. general Polish population
disease, neoplastic disease, depression, autoimmune diseases 
of the thyroid gland, etc.). There was no statistically signif-
icant difference in the percentage of hospitalised patients 
between groups with and without comorbidities (Fisher’s 
exact = 0.555). 
In 332 cases (84%), the infection was confirmed by PCR 
tested on a nasopharyngeal swab, in 39 (9.9%) cases the antigen 
test was positive, and 36 (9.1%) patients had antibodies against 
SARS-CoV-2. A combination of different tests was used in 
some subjects (Tab. 2).
The vast majority of the MS cohort was diagnosed with 
SARS-CoV-2 infection between October and December 
2020. The peak incidence of COVID-19 in the MS cohort 
generally overlapped with a trend in the general population 
in Poland (Fig. 2). A similar trend was observed with regard 
to hospitalisation (Fig. 3). We found that 264 (66.7%) pa-
tients reported contact with someone infected with SARS- 
-CoV-2, 82 (20.7%) patients denied contact with an infected 
person, and 50 (12.6%) cases had no information about any 
possible contact. 
The overall hospitalisation rate due to COVID-19 in the 
cohort was 6.81% (27 patients). Only one patient (0.3%) died 
due to COVID-19 infection, and three patients were treated 
with mechanical ventilation. The hospitalisation rate due to 
COVID-19 in the general Polish population was 7.98%, and 
the mortality rate was 2.46% [15]. The characteristics of hospi-
talised individuals in the MS cohort are set out in Table 3. The 
distribution of DMTs in the group of hospitalised patients and 
those who were not hospitalised is set out in Figure 4 and Table 4.
In our observation, patients treated with ocrelizumab 
were the most likely to be hospitalised while being infected 
with SARS-CoV-2 (p = 0.004). We did not consider interferon 
beta, glatiramer acetate, or dimethyl fumarate as increasing 
hospitalisation probability because univariate analysis did 
not confirm the significance of the result; 48 (12.1%) patients 
interrupted DMTs therapy during SARS-CoV-2 infection, 
and of these nine were hospitalised. A Mann-Whitney test 
showed no significant difference in disability (EDSS) between 
hospitalised and non-hospitalised patients in the cohort 
(p = 0.08211) (Fig. 5). 
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MS vs. general Polish population — hospitalisations due to COVID-19
Hospitalisations due to COVID-19 among the general population in Poland (left axis) 










































Figure 3. Hospitalisations due to COVID-19: MS vs. general Polish population
Table 3. Characteristics of hospitalised MS patients
Characteristics of hospitalised patients No. (%)
Number 27 (100)
Hospitalisation > 10 days 12 (44.4)
Hospitalisation < 10 days 15 (55.5)
Passive oxygen therapy 12 (44.4)





Convalescent plasma therapy 8 (29.6)
Antibiotics 23 (85.2)
0 50 100 150 200 250 300 350 400
The distribution of DMTs among patients with MS hospitalised due to COVID-19 
and patients who were not hospitalized 
Hospitalised  
Not hospitalised
  Interferon beta    Glatiramer acetate    Teriflunomide    Dimethyl fumarate    Fingolimod  
  Alemtuzumab    Natalizumab    Ocrelizumab    Cladrybine    Mitoxantrone    Ozanimod 
Figure 4. Distribution of DMTs among hospitalised and non-hospitalised MS patients
The mean age of hospitalised patients was 42.42 years, 
and the mean age of non-hospitalised patients was 39.88. 
A two-sided t-test suggested that this difference was not 
statistically significant (p = 0.209) (Fig. 6). The patients who 
were in need of oxygen therapy during COVID-19 were on 
average 6.17 years older than those who did not require oxygen 
support (p = 0.0227). 
Laboratory findings in the MS cohort are set out in Table 
5. There was no significant difference in the rate of hospitalisa-
tion between patients with and without lymphopenia (Fisher’s 
exact = 0.400). Patients with lymphopenia also did not require 
oxygen therapy (passive and active oxygen therapy) more 
often than did patients without lymphopenia (Fisher’s exact 
= 1.000). Symptoms presented during COVID-19 infection 
are set out in Table 6. 
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Table 4. Distribution of DMTs among hospitalised and non-hospitalised MS patients




Percentage of patients hospitalised on particular DMT 
in relation to all patients treated with particular DMT
Interferon beta 79 3 3.66 (3 out of 82)
Glatiramer acetate 37 5 11.90 (5 out of 42)
Dimethyl fumarate 151 13 7.93 (13 out of 164)
Teriflunomide 24 1 0.04 (1 out of 25)
Fingolimod 16 0 0
Natalizumab 35 0 0
Ocrelizumab 15 5 25 (5 out of 20)
Cladribine 5 0 0
Alemtuzumab 1 0 0
Mitoxantrone 3 0 0

























Figure 5. Distribution of EDSS among hospitalised and non-hospi-
talised patients in MS cohort
Figure 6. Distribution of age among hospitalised and non-hospital-
ised patients in MS cohort
Table 5. Laboratory findings among MS cohort during SARS-CoV-2 
infection
Laboratory findings during 
COVID-19 





(< 1 x 103/μL)
69 17.4
No lymphopenia 283 71.5
Lymphocytes result unknown 44 11.1
Leukopenia (< 3 x 103/μL) 13 3.3
No leukopenia 338 85.4
WBC result unknown 45 11.4
COVID-19 — coronavirus disease 2019; WBC — white blood cells
Discussion
To the best of our knowledge, this is the largest cohort of 
Polish MS patients with concomitant SARS-Cov-2 infection. 
Our study showed that the outcome of COVID-19 in the 
group of MS patients treated with DMTs compared to the 
general population was favourable. The SARS-CoV-2 infection 
among MS patients treated with DMTs is a concern for neurol-
ogists. The disease itself, and the use of immunomodulatory 
and immunosuppressive therapies, raise questions regarding 
the safety of MS patients during the pandemic. The cause 
and effect relationship between MS or accelerated neurode-
generation and viral infections has been under discussion for 
a long time [17, 18]. Recently, a nationwide study from Sweden 
showed that patients with MS are generally at a greater risk of 
infections [19]. Safety concerns among Polish MS patients is 
underlined by the fact that the prevalence of MS in Poland is 
tending to increase [20, 21].
Our findings suggest favourable infection outcomes in 
multiple sclerosis patients treated with different DMTs. Most 
patients had mild symptoms and did not require hospitalisa-
tion. Only 27 (6.81%) patients required hospitalisation, and 
only one patient (0.3%) died due to COVID-19 infection; three 
(0.76%) patients were treated with mechanical ventilation.
The second wave of COVID-19 in Poland emerged in early 
November 2020, and most cases of SARS-CoV-2 infection in 
219www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Agata Czarnowska et al., SARS-CoV-2 infection in MS patients treated with disease-modifying therapies
Table 6. Symptoms presented among patients with MS treated with DMTs 
during SARS-CoV-2 infection









Loss of smell 36.5 0.593
Muscle pain 35.7 1.471
Cough 34.9 1.791
Headache 28.1 0.709
Bone and joint pain 23.8 0.715
Chills 12.4 1.252
Loss of taste 12.2 1.723
Sore throat 11.6 0.923
Swelling of nasal mucosa 10.6 1.000






Abdominal pain 0.3 1.000
the MS cohort occurred during that time. The peak of MS 
patient hospitalisations was in October 2020, a month earlier 
than the peak of all hospitalisations due to COVID-19 in 
Poland (Fig. 3). It seems that at the beginning of the second 
wave of COVID-19 in Poland, doctors’ decisions to hospital-
ise MS patients with SARS-CoV-2 infection might have been 
determined largely due to the MS coexistence, rather than by 
the patient’s actual clinical condition. Initial observations on 
the favourable course of SARS-CoV-2 infection in MS patients 
meant that patients with MS were hospitalised less frequently 
than the general population at later periods. Finally, the hospi-
talisation rate and the mortality rate were slightly lower in our 
MS cohort compared to the general Polish population (6.81% 
vs. 7.98% and 0.3% vs. 2.46%, respectively).
The initial observational studies also suggest that patients 
with MS treated with DMTs are generally not at greater risk of 
severe COVID-19 infection [22–25]. However, in an Iranian 
MS cohort, the incidence of COVID-19 was comparable to 
the general population, but the hospitalisation rate was sig-
nificantly higher [26]. On the other hand, preliminary reports 
on Italian MS patients, as well as Brazilian and Chilean ob-
servations, showed that most patients with MS exhibit a mild 
course of SARS-CoV-2 infection despite the maintenance of 
DMTs [9, 27, 28]. The vast majority of our patients (87.9%) 
also continued treatment during their SARS-CoV-2 infec-
tion. Similar observations indicating no association between 
immunotherapy and the risk of COVID-19 were found in 
a group of more than 2,000 patients with NMOSD under 
appropriate immunotherapy in China. In this group, only two 
patients developed COVID-19 [29].
The favourable course of SARS-CoV-2 infection in MS 
patients could be due to the fact that most of them are younger 
and have fewer comorbidities than do patients from the general 
population. People aged over 60 and with multiple comor-
bidities often have severe disease [30, 31]. The median age in 
our cohort was 39. Age did not significantly differ between 
hospitalised and non-hospitalised patients with MS. How-
ever, the mean age of patients who required oxygen therapy 
was higher than those who did not require oxygen support. 
In a French multicentre study of 347 patients with MS who 
developed COVID-19, age, obesity, and MS-related disability 
were independent risk factors for more severe COVID-19, but 
DMT exposure was not associated with COVID-19 severity 
[22]. In our study, the degree of disability as assessed by EDSS 
was similar in hospitalised and non-hospitalised patients, but 
patients included in our study were in the early stage of the 
disease, with a median EDSS of 2.0. 
We found no association between comorbid diseases and 
the severity of SARS-CoV-2 infection. Most of our MS patients 
(more than 70%) had no comorbidities. Only one patient who 
required hospitalisation and oxygen therapy had more than 
one comorbid disease: hypertension and chronic obstructive 
pulmonary disease. Chronic pulmonary diseases are known 
to be a strong risk factor for serious COVID-19 [32]. Another 
risk factor for a severe clinical course of SARS-CoV-2 infection 
is diabetes mellitus [33] Among 12 (3%) patients with diabetes 
in our cohort, one required hospitalisation due to low satu-
ration and unilateral pneumonia. Two patients in our cohort 
had three comorbid diseases although none of them required 
hospitalisation during SARS-CoV-2 infection. We emphasise 
that comorbid diseases, known to be a worse prognostic factor 
for COVID-19, were only present in a minority of our patients, 
probably due to the young age of our cohort which consisted 
mainly of RRMS patients treated with DMTs. 
In Poland, from the beginning of the pandemic, only 
symptomatic patients were tested for SARS-CoV-2. Therefore, 
the MS cohort in our study consisted mostly of those who had 
symptoms of COVID-19. In a few asymptomatic patients, 
the infection was detected for professional reasons or before 
a planned hospitalisation.  
The most common symptoms of SARS-CoV-2 infection 
presented in the Polish MS cohort were fever, fatigue, cough 
and hyposmia. These symptoms were similar to those reported 
from multicentre studies of general populations worldwide 
[35]. The course of the disease did not differ greatly between 
patients with MS and the general population. About 20% of 
our subjects denied contact with an infected individual. This 
shows that asymptomatic carriers can be a major threat [34].
Among the MS cohort, we registered one death during the 
course of COVID-19. The patient with a fatal outcome was 
220
Neurologia i Neurochirurgia Polska 2021, vol. 55, no. 2
www.journals.viamedica.pl/neurologia_neurochirurgia_polska
a 51-year-old female non-smoker with comorbid hypertension. 
She had been diagnosed with relapsing-remitting multiple 
sclerosis 19 years prior to infection. Her EDSS was 6.0, and 
she has been treated with ocrelizumab for six years (no other 
immunomodulatory treatment was used before). The last 
dose of ocrelizumab was given in February 2020, and she was 
diagnosed with COVID-19 in August 2020 (at the moment of 
COVID-19 diagnosis there was no lymphopenia). 
In the study group, three patients required mechanical 
ventilation (one male, two female). Interestingly, they were 
younger (31, 38, and 39 years) and did not suffer from any 
comorbid diseases. Maximal EDSS in this group was 4.0, and 
the longest duration of the disease was eight years. They were 
treated with glatiramer acetate, interferon beta, and dimethyl 
fumarate, respectively.
One major concern for neurologists treating MS patients 
with SARS-CoV-2 infection is the safety of B-cell depleting 
therapies. B-cells are responsible for generating neutralising 
antibodies. Therefore, there is uncertainty regarding the clini-
cal course of the infection and the effectiveness of the reaction 
to future vaccination. Most data does not support higher sus-
ceptibility toward more severe SARS-CoV-2 infection among 
patients treated with B-cell depleting therapies [22, 23, 36, 37]. 
However, Sormani et al. showed an increased risk of severe 
COVID-19 disease in patients treated with an anti-CD20 agent 
[38]. Sharifian-Dorche et al. recently reviewed almost 2,500 MS 
patients with COVID-19 from different studies. They found 
that patients treated with anti-CD20 agents (ocrelizumab, 
rituximab) had the highest mortality rate during the infection 
[39]. In our cohort, patients treated with ocrelizumab had 
a higher risk of hospitalization due to SARS-CoV-2 infection. 
However, three out of five patients hospitalized theated with 
these therapy suffered form PPMS. Our observation of patients 
with COVID-19 while being on ocrelizumab treatment is 
limited to 20 individuals, and thus we are not drawing any 
definite conclusions. Nonetheless, we draw attention to the 
need to closely monitor patients treated with anti-CD20 agents 
during SARS-CoV-2 infection.
Patients with progressive forms of MS are more disabled 
and tend to have a more severe clinical course of SARS- 
-CoV-2 infection [22, 40]. Here, 24 (6%) patients were diag-
nosed with progressive MS: 22 patients with PPMS and two 
with SPMS. Among patients with progressive MS subtypes, 
four required hospitalisation and passive oxygen therapy. The 
statistical difference in the course of SARS-CoV-2 infection 
between RRMS and progressive phenotypes of the disease 
was not significant in our study. The numbers of patients with 
PPMS and SPMS were limited, and final conclusions should 
only be drawn from a larger observation. 
Importantly, MS patients with lymphopenia were not 
hospitalised more often than patients without lymphopenia. 
This information is an additional indication for how to con-
sider DMT continuation in real-world practice. Our findings 
are consistent with the initial Dutch experience, but far more 
data is needed to be certain that lymphopenia is not associated 
with a more severe course of the disease [41].
In our MS cohort, any obvious advantage of one drug over 
another was not found in hospitalised patients or in those who 
needed oxygen therapy. Some studies have shown a trend for 
an increased risk of infection with immune-resetting drugs 
versus injectables, but no final conclusions were drawn be-
cause of the small number of observations [42]. In our study, 
none of the 35 MS patients treated with natalizumab required 
hospitalisation or oxygen therapy. Only one of the 25 patients 
treated with teriflunomide and only three of the 82 patients 
treated with interferon beta were hospitalised.  
Some studies have shown a potential protective role of 
interferons in COVID-19, as these are natural antiviral and 
anti-inflammatory proteins [43, 44]. There are also studies 
pointing to some antiviral activity of teriflunomide [45]. In 
our MS cohort, the percentage of patients treated with inter-
ferons beta (20.70% of all patients) in relation to those treated 
with dimethyl fumarate (41.41% of all patients) is much lower 
than in the entire Polish MS population. In Poland, dimethyl 
fumarate and interferons beta are used by similar numbers of 
MS patients (5,939 and 6,095 patients in 2019 respectively). 
In our MS cohort, patients were most frequently treated with 
dimethyl fumarate, and 13 of them (7.93% of the dimethyl 
group) needed hospitalisation. However, our cohort is not 
large enough to draw conclusions about the use of DMT 
and any protective or non-protective role during SARS- 
-CoV-2 infection. 
A potential source of bias in our study is that we included 
only patients who were treated in specialised MS centres. 
Also, immobile patients with a high degree of motor and/
or cognitive disability were not included in our study, and 
in that group the outcomes could potentially be worse. Fi-
nally, we could not assess differences between treated versus 
non-treated MS patients, since our study group only included 
subjects on DMTs.
Conclusions 
Our study did not provide evidence of a more severe course 
of COVID-19 in a group of Polish patients treated with several 
DMTs. Most patients did not require hospitalisation or oxygen 
therapy. Only one patient died. We did not observe a significant 
difference in the severity of SARS-CoV-2 infection regarding 
age, MS duration, the degree of disability as measured by 
EDSS, presence of comorbidities, lymphocyte count, or the 
use of different DMTs. There is an urgent need to continue 
multicentre data collection to increase the understanding of 
SARS-CoV-2 infection impact on MS course in patients treated 
with DMTs, especially concerning the long-term complications 
after SARS-CoV-2 infection. 
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